Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Bible KC, Menefee ME, Lin CJ, Millward MJ, Maples WJ, Goh BC, Karlin NJ, Kane MA, Adkins DR, Molina JR, Donehower RC, Lim WT, Flynn PJ, Richardson RL, Traynor AM, Rubin J, LoRusso PM, Smallridge RC, Burton JK, Suman VJ, Kumar A, Voss JS, Rumilla KM, Kipp BR, Chintakuntlawar AV, Harris P, Erlichman C. Bible KC, et al. Among authors: erlichman c. Thyroid. 2020 Sep;30(9):1254-1262. doi: 10.1089/thy.2019.0269. Epub 2020 Jul 29. Thyroid. 2020. PMID: 32538690 Free PMC article. Clinical Trial.
Competitive protein binding assay of methotrexate.
Erlichman C, Donehower RC, Myers CE. Erlichman C, et al. Methods Enzymol. 1982;84:447-58. doi: 10.1016/0076-6879(82)84032-9. Methods Enzymol. 1982. PMID: 7098962 No abstract available.
Molecular markers in male breast carcinoma.
Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN, Donohue JH. Rayson D, et al. Among authors: erlichman c. Cancer. 1998 Nov 1;83(9):1947-55. doi: 10.1002/(sici)1097-0142(19981101)83:9<1947::aid-cncr10>3.0.co;2-j. Cancer. 1998. PMID: 9806653
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL. Pitot HC, et al. Among authors: erlichman c. Clin Cancer Res. 2000 Jun;6(6):2236-44. Clin Cancer Res. 2000. PMID: 10873073 Clinical Trial.
243 results